Swiss ministers have met with senior executives of pharmaceutical companies Roche and Novartis to discuss the outlook for the ...

The pharma company said the drug combined with eltrombopag demonstrated a significant improvement in time to treatment ...

Packaged breads and refined grain products may increase the odds of developing IBD, while minimally processed fresh bread and ...

European shares were broadly flat on Monday, as investors refrained from making big bets ahead of a key U.S. inflation data, ...

Patients with psoriasis have significantly more difficulty sleeping, particularly in new environments, than matched ...

And if you're looking for top dividend-paying companies to put your money in right now, let's consider two excellent ...

The Swiss government has met with senior executives from Roche (ROG: SIX) and Novartis (NOVN: VX) to discuss the outlook for ...

The overwhelming federal nature of this subject is apparent,” the lawsuit alleges. “States are not free to tinker with ...

Novartis may have abandoned one Sjögren's syndrome asset this year, but it looks like the drugmaker has a winner on its hands ...

Novartis' ianalumab plus eltrombopag significantly extended treatment response and improved platelet counts in a Phase 3 ...

If approved, Novartis' ianalumab would become the first targeted treatment for patients with Sjögren’s disease.

A mere 24 hours after Novartis' ianalumab hit the mark in two phase 3 trials in Sjogren's syndrome, the drug has delivered ...